News A vaccine adcomm expert criticised RFK Jr – now he's out A prominent critic of RFK Jr's approach to vaccination regulation, Dr Paul Offit, has been removed from an influential FDA advisory committee.
News GSK's growth plans dented by Blenrep setback FDA advisors have voted that the benefit/risk profile of GSK's multiple myeloma therapy, Blenrep, does not support its approval in the US.
News Mixed outcomes for pharma in big week for FDA adcomms There was good news for Johnson & Johnson at this week's ODAC meetings, but not for Roche, UroGen, and Pfizer.
Market Access New FDA head says no more pharma on advisory committees The announcement signals a new administration attempting to distance itself from industry, but the actual impact seems small.